首页    期刊浏览 2024年11月26日 星期二
登录注册

文章基本信息

  • 标题:Health-related quality of life in patients with depression treated with duloxetine or a selective serotonin reuptake inhibitor in a naturalistic outpatient setting
  • 本地全文:下载
  • 作者:Jihyung Hong ; Diego Novick ; William Montgomery
  • 期刊名称:Patient Preference and Adherence
  • 印刷版ISSN:1177-889X
  • 电子版ISSN:1177-889X
  • 卷号:9
  • 页码:1481-1490
  • DOI:10.2147/PPA.S89870
  • 出版社:Dove Medical Press Ltd
  • 摘要:Purpose: To assess the levels of quality of life (QoL) in major depressive disorder (MDD) patients treated with either duloxetine or a selective serotonin reuptake inhibitor (SSRI) as monotherapy for up to 6 months in a naturalistic clinical setting mostly in the Middle East, East Asia, and Mexico. Patients and methods: Data for this post hoc analysis were taken from a 6-month prospective observational study involving 1,549 MDD patients without sexual dysfunction. QoL was measured using the EQ-5D instrument. Depression severity was measured using the Clinical Global Impression of Severity and the 16-item Quick Inventory of Depressive Symptomatology Self-Report (QIDS-SR16), while pain severity was measured using the pain items of the Somatic Symptom Inventory. Regression analyses were performed to compare the levels of QoL between duloxetine-treated (n=556) and SSRI-treated (n=776) patients, adjusting for baseline patient characteristics. Results: These MDD patients, on average, had moderately impaired QoL at baseline, and the level of QoL impairment was similar between the duloxetine and SSRI groups (EQ-5D score of 0.46 [SD =0.32] in the former and 0.47 [SD =0.33] in the latter, P =0.066). Both descriptive and regression analyses confirmed QoL improvements in both groups during follow-up, but duloxetine-treated patients achieved higher QoL. At 24 weeks, the estimated mean EQ-5D score was 0.90 in the duloxetine cohort, which was statistically significantly higher than that of 0.83 in the SSRI cohort ( P <0.001). Notably, pain severity at baseline was also statistically significantly associated with poorer QoL during follow-up ( P <0.001). In addition, this association was observed in the subgroup of SSRI-treated patients ( P <0.001), but not in that of duloxetine-treated patients ( P =0.479). Conclusion: Depressed patients treated with duloxetine achieved higher QoL, compared to those treated with SSRIs, possibly in part due to its moderating effect on the link between pain and poorer QoL.
  • 关键词:depression; antidepressant; duloxetine; SSRI; quality of life
国家哲学社会科学文献中心版权所有